Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) requiring therapy~  * Primary resistance, defined as disease progression without response during at least 2 courses of myelosuppressive therapy OR~ * Relapsed disease, defined as a response (remission or plateau) followed by relapse on or off prior therapy~ * At least 1 prior regimen must have contained fludarabine~* Intermediate or high-risk CLL~  * Intermediate-risk disease must satisfy at least 1 of the following criteria for active disease:~    * Massive or progressive splenomegaly and/or lymphadenopathy~      * Spleen tip greater than 6 cm below costal margin~   * More than 10% weight loss within the past 6 months~   * Grade 2 or 3 fatigue~   * Fevers greater than 100.5 degrees F or night sweats for more than 2 weeks without evidence of infection~   * Progressive lymphocytosis with an increase of more than 50% over a 2-month period or an anticipated doubling time of less than 6 months~   * Worsening anemia or thrombocytopenia~* Measurable disease with all of the following:~  * Absolute lymphocytosis greater than 5,000/mm\^3~ * Lymphocytosis of small to moderate-size lymphocytes with less than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically determined by manual differential~ * Bone marrow aspirate smear with at least 30% nucleated cells that are lymphoid or a bone marrow core biopsy showing lymphoid infiltrates compatible with CLL~ * Normocellular or hypercellular bone marrow~ * Lymphocyte immunophenotype that shows a predominant B-cell monoclonal population~* No Rai stage 0 CLL or stable CLL not requiring therapy~* No secondary leukemia or history of antecedent hematologic disorder prior to initial onset of CLL (e.g., myelodysplasia)~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~* Platelet count at least 50,000/mm\^3 (hematopoietic growth factor or transfusion independent)~* Negative Coombs' test~* No bleeding or coagulation disorder~* No history of hemolytic anemia, including autoimmune hemolytic anemia~* No history of autoimmune thrombocytopenia~Hepatic:~* Albumin at least 3.0 g/dL~* Bilirubin no greater than 2 mg/dL~* AST no greater than 1.5 times upper limit of normal (ULN) (5 times ULN if due to CLL)~* PT no greater than 1.5 times ULN OR~* INR no greater than 1.3~* PTT no greater than 1.5 times ULN~* No chronic hepatitis or cirrhosis~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No uncontrolled congestive heart failure~* No active symptoms of coronary artery disease (i.e., uncontrolled arrhythmia or recurrent chest pain despite prophylactic medication)~* No New York Heart Association class III or IV disease~* No cardiovascular signs or symptoms grade 2 or greater~Other:~* Able to maintain an ambulatory infusion pump~* HIV negative~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No known hypersensitivity to phosphorothioate-containing oligonucleotides, fludarabine, or cyclophosphamide~* No concurrent medical disease that would preclude study participation~* No uncontrolled seizure disorder~* No unresolved serious infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior autologous or allogeneic stem cell transplantation~* At least 3 weeks since prior immunologic therapy, cytokine therapy, vaccine therapy, or other biologic therapy for CLL and recovered~* No concurrent interleukin-11~Chemotherapy:~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy and recovered~Endocrine therapy:~* No concurrent corticosteroid therapy~Radiotherapy:~* At least 3 weeks since prior radiotherapy for CLL and recovered~Surgery:~* No prior organ allograft~* At least 3 weeks since prior major surgery for CLL and recovered~Other:~* At least 3 weeks since other prior therapy for CLL and recovered~* No other concurrent investigational therapy~* No concurrent therapeutic anticoagulation~* No concurrent immunosuppressive drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).